Publisher · 6 documents · 37 figures
State Council of China
37 verified figures from 6 publications by State Council, a government body. Every figure links to the document and sentence it came from.
Documents used
Every publication we have taken a number from, with the date we read it and the link status at that time.
| Document | Type | Retrieved | Link | Data points |
|---|---|---|---|---|
| Measures facilitate approval of 48 first-in-class innovative drugs Licence: See source | Press release | 17 Sep 2026 | Reachable | 11 |
| 2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药_政策解读_中国政府网 Licence: See source | Press release | 17 Sep 2026 | Reachable | 10 |
| Value of China's innovative drug out-licensing deals hit new high in H1 Licence: See source | Press release | 17 Sep 2026 | Reachable | 4 |
| China updates national medical insurance catalog, adds 114 new drugs Licence: See source | Press release | 17 Sep 2026 | Reachable | 4 |
| 全面深化监管改革 缩短临床试验审评审批时限——加快创新药和医疗器械上市_政策解读_中国政府网 Licence: See source | Press release | 17 Sep 2026 | Reachable | 2 |
| China to expand health insurance coverage for innovative drugs Licence: See source | Press release | 17 Sep 2026 | Reachable | 6 |
Measures from this publisher
Every measure taken from State Council, with its latest value and trend. Each value opens its record.
Market size and output 7
Show 1 more measure
Adoption and share 3
Growth and change 3
Other measures 20
Show 14 more measures
- Drugs removed from national reimbursement drug list 43
- Globally new innovative drugs added to reimbursement drug list 38
- Innovative drug negotiation success rate 90%
- Innovative drug out-licensing deal value (half year) 100 billion USD
- Innovative drugs added to national health insurance catalog 50
- Innovative drugs added to national health insurance drug list 199
- Innovative drugs approved via priority review pathway 17
- Innovative drugs granted conditional market approval 11
- Medicines added to national health insurance drug list 949
- Negotiated or bid drugs added to national reimbursement drug list (annual) 89
- Newly added drugs in national reimbursement drug list 114
- Newly added drugs in national reimbursement drug list (annual) 91
- Projected patient out-of-pocket burden reduction 50 billion CNY
- Rare disease drug varieties approved 39
33 measures. Each name opens the full series; each value opens the record with its source evidence.
Cite this page
Data on this page is published under CC BY 4.0. Credit State Council of China as the original publisher; each record page carries its own citation.
State Council of China. Retrieved from StatOrigin: https://statorigin.org/sources/state-council-of-china
Related
Industries using this source
Last verified 27 September 2026. Link status is rechecked weekly.